APG-1387
Chronic Hepatitis B
Key Facts
About Ascentage Pharma Group
Ascentage Pharma Group is a China-based, publicly traded biotech with a mission to develop transformative therapies by targeting apoptosis and autophagy pathways. The company has established a robust clinical pipeline, with multiple assets in global trials for various cancers, positioning its lead candidates as potential best-in-class agents. Its integrated strategy combines proprietary target discovery with clinical development and manufacturing to advance novel treatments for global markets. Key achievements include advancing several programs into mid- and late-stage clinical development and building a strong intellectual property portfolio around its core platform.
View full company profileAbout Ascentage Pharma Group
Ascentage Pharma Group is a China-based, publicly traded biotech with a mission to develop transformative therapies by targeting apoptosis and autophagy pathways. The company has established a robust clinical pipeline, with multiple assets in global trials for various cancers, positioning its lead candidates as potential best-in-class agents. Its integrated strategy combines proprietary target discovery with clinical development and manufacturing to advance novel treatments for global markets. Key achievements include advancing several programs into mid- and late-stage clinical development and building a strong intellectual property portfolio around its core platform.
View full company profileOther Chronic Hepatitis B Drugs
| Drug | Company | Phase |
|---|---|---|
| ZM-H1505R | Zhimeng Biopharma | Phase 1 |
| Undisclosed CAM | Zhimeng Biopharma | Clinical |
| Undisclosed Immunomodulator | Zhimeng Biopharma | Clinical |
| Selgantolimod (GS-9688) | Gilead | Phase 2 |
| Bepirovirsen | GSK | Phase III |
| BRII-835 (VIR-2218) + BRII-179 (VBI-2601) | Brii Biosciences | Phase 2 |
| BRII-179 (VBI-2601) | Brii Biosciences | Phase 2a/2b |
| VIR-3434 | Brii Biosciences | Preclinical/Phase 1 (ex-China) |
| Collaboration with Aligos Therapeutics | Amoytop Biotech | Clinical |
| JNJ-3989 | Johnson & Johnson | Phase 2 |
| VTP-300 | Barinthus Biotherapeutics | Phase 1b/2a |